news and updates

12.21.2015

AureoGen closes a licensing agreement with Merck.

read more ...


Contact us

AureoGen Biosciences 
4717 Campus Drive Suite 2300 
Kalamazoo, MI 49008 
1.269.353.3805   

news

December 21, 2015 AureoGen closes a licensing agreement with Merck for the use of AureoGen’s proprietary chemistry and compounds for the development of medicines for infectious disease, including systemic fungal infections. (Press Release)

January 31, 2014 Aureogen receives a $340,000 investment/convertible loan from the Western Michigan University (WMU) Bioscience Research and Commercialization Center (BRCC).

February 11, 2011 AureoGen is awarded a $487,411 Competitive renewal grant of the NIH Phase II SBIR project Novel Antifungals by Engineering a NRPS gene

October 29, 2010 AureoGen receives a $244,479. Qualifying Therapeutic Discovery Project award.

April 30, 2009 AureoGen receives a Michigan 50 Companies to Watch award from The Edward Lowe Foundation in association with the Michigan Economic Development Corporation, Michigan Small Business & Technology Development Center, Small Business Association of Michigan, the U.S. Small Business Administration.

February 19, 2009 Ake Elhammer and AureoGen Biosciences receives a Best Technology of the Year 2008 award from the Michigan New Enterprise Forum

June 13, 2008 AureoGen is awarded a $286,746 NIH SBIR Phase I grant for a project entitled, Generation of novel drugs against drug resistant bacteria through engineering of the empedopeptin biosynthesis gene.

March 27, 2008 AureoGen is awarded a $600,000 NIH SBIR Phase I ATP grant (two years) for a project entitled, Generation of novel HCV drugs through engineering of the cssA gene .

June 22, 2007 AureoGen is awarded a $381,116 NIH SBIR Phase I grant for a project entitled A Bacitracin derivative for systemic use.

January 30, 2007 - AureoGen Biosciences enter into a license agreement with Takara Bio Inc., a $140 million biotech company located in Otsu, Japan. The agreement will provide AureoGen access to several patent protected antibiotic compounds, as well as a proprietary organism that produces the potent antifungal compound Aureobasidin A (AbA). AbA is the primary (genetic engineering) target for AureoGen’s efforts to prepare a novel broad spectrum antifungal drug.

October 15, 2006 - AureoGen Biosciences moves into a new 4,000 sq.ft. facility at 6475 Technology Avenue in Kalamazoo, MI. The new facility includes 3,000 sq.ft. of newly constructed state-of-the art lab space for the company research.

May 15, 2006 - AureoGen Biosciences receives a Small Business Innovation Research (SBIR) grant from the National Institutes of Allergy and Infectious Diseases. The successful completion of the AureoGen’s Phase I project “Novel Antifungals by Engineering a NRPS gene” (see above) allowed the company to apply for, and be awarded, Phase II funding for this project. The Phase II SBIR grant amounts to $1,978,701.00, over a period of three years.

April 1, 2005 - AureoGen Biosciences receives a $225,000 investment from the Bioscience Research and Commercialization Center (BRCC) at the Western Michigan University in Kalamazoo MI.

September 28th, 2004 - AureoGen Biosciences, Inc., receives award from the National Institutes of Standards and Technology Advanced Technology Program (NIST/ATP) -- AureoGen Biosciences Inc., was selected from among 870 applicants to receive one of the 32 NIST/ATP awards granted for 2004. [With a funding rate of only 3.68%, 2004 is the most competitive year since inception of the NIST/ATP program in 1990.] AureoGen’s three year grant totals $1,450,508.00 and will be used to fund a project entitled “A Genetic Engineering Technology Platform for Production of Novel Cyclic Peptide-Based Drugs”. The total cost of the project is $2,242,542.00, with the remaining funds being contributed as a match from AureoGen.

September 17th, 2004 - AureoGen Biosciences, Inc., receives Small Business Innovation Research (SBIR)award from the National Institutes of Allergy and Infectious Diseases -- AureoGen Biosciences Inc., was awarded Phase I funding for a project entitled Novel Antifungals by Engineering a NRPS gene. The Phase I SBIR grant amounts to $162,982.00 and is to fund the initial (6 months) of the project. Successful completion of the Phase I research will allow AureoGen to apply for continued, Phase II funding for completion of the later stages of the project. The Phase I grant is scheduled to start October 1, 2004 and be completed by March 31, 2005.

June 29th, 2004 - AureoGen Biosciences Inc., is a Michigan Tri-Technology Corridor (MTTC) 2004 Award Winners -- AureoGen Biosciences Inc., was awarded a three year, $1,994,476, convertible loan from the MTTC. The MTTC loan is part of the Michigan Economic Development Corporation efforts to promote the development of new businesses in the State of Michigan. AureoGen’s award will be used for the development of genetic tools and methodologies that will allow for efficient genetic engineering of cyclic peptide producing organisms. The start date for the award is October 31, 2004, and the award is for three years with annual milestones to be completed for continued funding. As part of the award, AureoGen has granted Western Michigan University a total of $371,607.00 to fund research in the laboratory of Dr. John R. Geiser, at Department of Biological Sciences. Dr. Geiser’s laboratory will work on identifying new ways to engineer the biosynthesis complexes responsible for production of cyclic peptides.

September 4th, 2003- AureoGen Biosciences, Inc., is awarded $200,000 in startup funding from the Michigan Economic Development Corporation.